* Treatment of PCP caused by Pneumocystis jirovecii * Prevention of PCP in adults with HIV who have one or both of the following: * History of PCP * CD4+ count ≤ 200mm³ * Treatment of leishmaniasis * Treatment of African trypanosomiasis caused by Trypanosoma brucei gambiense * Balamuthia infections *<unk>  is classified as an orphan drug by the U.S. Food and Drug Administration Other uses * Use as an antitumor drug has also been proposed. *<unk>  is also identified as a potential small molecule antagonist that disrupts this interaction between S100P and RAGE receptor. Special Populations Pregnancy It has not been shown to cause birth defects in animal studies when given intravenously. There are no controlled studies to show if<unk>  can harm the fetus in pregnant women. It is only recommended if the drug of choice trimethoprim-sulfamethoxazole is contraindicated. Breastfeeding There is no information regarding the excretion of<unk>  in breast milk, but since the adverse effects on breastfed infants are unknown currently, it is recommended by the manufacturer for the infant to not be breastfed or for the mother to stop the drug. Risks versus benefits for the mother should be considered when making this decision. Children<unk>  can be used in the prevention of PCP in children with HIV who cannot tolerate Trimethoprim/Sulfamethoxazole and can use a nebulizer. Intranvenous solutions of<unk>  should only be used in children with HIV older than 2 years old when other treatments are unavailable Elderly There is no data for the use of<unk>  in this specific population.
Pentamidine
Isocarboxazid
Trenbolone hexahydrobenzylcarbonate
Delamanid
Dimetacrine
Astemizole
Quinine
Artesunate